The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | Transplant-related toxicity in pediatric patients with SCD or thalassemia
Jean-Hugues Dalle, MD, PhD, Université Paris Cité, Paris, France, discusses the challenges in preventing acute toxicity in pediatric patients undergoing myeloablative conditioning regimens, particularly those using busulfan. While preventive measures are limited, Prof. Dalle emphasizes the importance of considering factors like nutritional status and hemoglobin levels before transplantation and having thorough discussions with families about the risks to mentally prepare them for the transplant journey. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Vertex.
